Eli Lilly (LLY) stock surges after releasing promising test results ... Semaglutide, like I just said, and remain confident in Orforglipron's ability to show 13 to 15% weight loss in the upcoming ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Of the participants, 60% (n = 120) were treated with tirzepatide and 40% (n = 80) with semaglutide ... months while taking GLP/GIP weight loss medications. The results suggest that, with proper ...

Injectable drugs require refrigeration when they are stored or transported, and the pill potentially opens up the market ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill ... as we think about Semaglutide, which is ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Injectable medications originally developed for the treatment of diabetes are also effective for weight loss and have surged ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

A daily weight loss pill that works ... have on obesity alone, with results expected to be published later this year. Previous studies found people injected with semaglutide, the active ingredient ...

Ozempic (semaglutide) and Victoza (liraglutide ... Ozempic and Victoza are not approved for weight loss or weight management. However, some people using Ozempic and Victoza in studies did lose ...